$3.51
Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates
Voyager Therapeutics: Q2 Earnings Snapshot
Overview
52-week range
$2.94
$5.55
22% of range
Avg surprise (last 3)
-19.1%
Avg reaction (last 2)
-6.0%
0% positive
Latest IV / EM
34%
EM ±5.7% · $4 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.40 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.47 | $-0.54 | +13.0% | +11.3% | -5.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.47 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.57 | $-0.48 | -18.8% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.53 | $-0.35 | -51.4% | — | -6.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.18 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.59 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.51 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $2.94 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $3M | — | $13M | $5M | $6M | — | $25M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-26M | $-30M | — | $-31M | $-37M | $-35M | — | $-14M |
| Net income | $-24M | $-28M | — | $-28M | $-33M | $-31M | — | $-9M |
| EPS (diluted) | $-0.40 | $-0.47 | — | $-0.47 | $-0.57 | $-0.53 | — | $-0.16 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $36M | $43M | $65M | $45M | $44M | $75M | $71M | $113M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $125M | $147M | $203M | $220M | $228M | $245M | $277M | $373M |
| Total assets | $198M | $219M | $252M | $288M | $322M | $353M | $393M | $426M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $43M | $46M | $56M | $68M | $78M | $81M | $93M | $96M |
| Total equity | $154M | $174M | $196M | $220M | $244M | $273M | $300M | $330M |